Teva/Ranbaxy launch Accupril generic
Executive Summary
Teva/Ranbaxy launch first generic version of Pfizer's Accupril (quinapril) Dec. 15 following FDA approval of Ranbaxy's ANDA. The generic is being manufactured by Ranbaxy, with Teva handling distribution and marketing pursuant to an exclusive supply agreement between the companies. Teva relinquished its 180-day exclusivity, allowing FDA to approve Ranbaxy's ANDA; five other companies hold tentative ANDA approval. Court rulings finding Teva's ANDA infringed a valid Pfizer patent prevented Teva from bringing its own generic to market (1"The Pink Sheet" July 5, 2004, p. 11)...
You may also be interested in...
Pfizer sues over Accupril generic
Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1"The Pink Sheet" Dec. 20, 2004, In Brief)...
Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.